Feedback
Settings

Settings

Goto Application

1,906 results
Offices all Languages Stemming true Single Family Member false Include NPL false
RSS feed can only be generated if you have a WIPO account

Save query

A private query is only visible to you when you are logged-in and can not be used in RSS feeds

Query Tree

Refine Options

Offices
All
Specify the language of your search keywords
Stemming reduces inflected words to their stem or root form.
For example the words fishing, fished,fish, and fisher are reduced to the root word,fish,
so a search for fisher returns all the different variations
Returns only one member of a family of patents
Include Non-Patent literature in results

Full Query

CHEM:(GRYSXUXXBDSYRT-WOUKDFQISA-N)

Side-by-side view shortcuts

General
Go to Search input
CTRL + SHIFT +
Go to Results (selected record)
CTRL + SHIFT +
Go to Detail (selected tab)
CTRL + SHIFT +
Go to Next page
CTRL +
Go to Previous page
CTRL +
Results (First, do 'Go to Results')
Go to Next record / image
/
Go to Previous record / image
/
Scroll Up
Page Up
Scroll Down
Page Down
Scroll to Top
CTRL + Home
Scroll to Bottom
CTRL + End
Detail (First, do 'Go to Detail')
Go to Next tab
Go to Previous tab

Analysis

1 / 191
1.WO/2026/014855FUSION PROTEIN COMPRISING APOLIPOPROTEIN AND FC REGION-BINDING PEPTIDE AND USES THEREOF
WO - 15.01.2026
Int.Class C07K 14/775
CCHEMISTRY; METALLURGY
07ORGANIC CHEMISTRY
KPEPTIDES
14Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
435from animals; from humans
775Apolipopeptides
 Appl.No PCT/KR2025/009774 Applicant RNAGENE INC. Inventor LEE, Woo Ghil
The present invention relates to a fusion protein and a use thereof, wherein the fusion protein comprises: an apolipoprotein or a fragment thereof; and an Fc-binding peptide (Fc BP) or a fragment thereof. According to one aspect, a lipid carrier comprising the fusion protein was found to exhibit remarkably improved targeting efficiency, and thus can be used to deliver an active substance to a desired target.
2.WO/2026/015876IMPROVED METHODS FOR IN VITRO TRANSCRIPTION
WO - 15.01.2026
Int.Class C12P 19/34
CCHEMISTRY; METALLURGY
12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
PFERMENTATION OR ENZYME-USING PROCESSES TO SYNTHESISE A DESIRED CHEMICAL COMPOUND OR COMPOSITION OR TO SEPARATE OPTICAL ISOMERS FROM A RACEMIC MIXTURE
19Preparation of compounds containing saccharide radicals
26Preparation of nitrogen-containing carbohydrates
28N-glycosides
30Nucleotides
34Polynucleotides, e.g. nucleic acids, oligoribonucleotides
 Appl.No PCT/US2025/037414 Applicant ARCTURUS THERAPEUTICS, INC. Inventor HILL, Brett Dallas
Disclosed herein are methods of producing transcribed RNA product with increased yield and reduced RNA degradation.
3.WO/2026/010855MODIFIED RNA FOR INCREASING PROTEIN EXPRESSION
WO - 08.01.2026
Int.Class C12N 15/67
CCHEMISTRY; METALLURGY
12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
15Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
09Recombinant DNA-technology
63Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
67General methods for enhancing the expression
 Appl.No PCT/US2025/035891 Applicant TRILINK BIOTECHNOLOGIES, LLC Inventor XU, Chunping
Described herein are modified RNA molecules where a modified NTP is covalently attached to the 3' end of the poly-A region of the RNA molecule. Methods of synthesizing said RNAs are also provided herein.
4.WO/2026/010842USE OF LIPID NANOPARTICLE MRNA FOR TERT SPECIFIC CANCER IMMUNOTHERAPY
WO - 08.01.2026
Int.Class A61K 39/00
AHUMAN NECESSITIES
61MEDICAL OR VETERINARY SCIENCE; HYGIENE
KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
39Medicinal preparations containing antigens or antibodies
 Appl.No PCT/US2025/035853 Applicant THE TRUSTEES OF THE UNIVERSITY OF PENNSYLVANIA Inventor VONDERHEIDE, Robert H.
The present invention relates to compositions for inducing an immune response against a tumor antigen in a subject, the composition comprising at least one mRNA encoding at least one tumor antigen selected from the group consisting of hTERT, mTERT, and KRASG12D, encapsulated in a lipid nanoparticle.
5.WO/2026/009141IONIZABLE CATIONIC COMPOUND
WO - 08.01.2026
Int.Class A61K 31/7088
AHUMAN NECESSITIES
61MEDICAL OR VETERINARY SCIENCE; HYGIENE
KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
31Medicinal preparations containing organic active ingredients
70Carbohydrates; Sugars; Derivatives thereof
7088Compounds having three or more nucleosides or nucleotides
 Appl.No PCT/IB2025/056656 Applicant SEQIRUS INC. Inventor YANG, Cangjie
Novel ionizable lipid compounds of Formula I are provided. The use of the compounds in forming lipid nanoparticles is described. The lipid nanoparticles may encapsulate a therapeutic, such as a nucleic acid, and these may be used in the delivery of the therapeutic and in methods of treating certain conditions or for inducing an immune response.
6.WO/2026/006238LONG NON-CODING RNA AND N6-METHYLADENOSINE IN TYROSINE KINASE INHIBITOR RESISTANCE
WO - 02.01.2026
Int.Class C12Q 1/6886
CCHEMISTRY; METALLURGY
12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
QMEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
1Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
68involving nucleic acids
6876Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes
6883for diseases caused by alterations of genetic material
6886for cancer
 Appl.No PCT/US2025/034936 Applicant METROHEALTH VENTURES LLC Inventor LIU, Shujun
A method of obtaining a prognosis for a subject who has or has had leukemia who has been or is being treated with a tyrosine kinase inhibitor (TKI) is described. The method includes determining the levels of one or more of 1) total N6-methyladenosine (m6A), 2) long non-coding RNA (lncRNA) bearing m6A sites, 3) lncRNA-specific m6A, 4) the fat mass and obesity-associated gene (FTO) in a biological sample from the subject; and assigning a poor prognosis or poor TKI responder status to the subject if the level of m6A, lncRNA being m6A sites, lncRNA-specific m6A, and/or FTO is higher than the one or more corresponding control values obtained from a healthy subject. Methods of treating a subject having TKI-resistant leukemia and methods of predicting TKI resistance in a subject having leukemia are also described.
7.WO/2026/006830COMPOSITIONS AND METHODS OF TREATING DISEASES AND DISORDERS CHARACTERIZED BY BLOOD-BRAIN BARRIER DETERIORATION OR REACTIVE OXYGEN SPECIES GENERATION
WO - 02.01.2026
Int.Class A61K 31/395
AHUMAN NECESSITIES
61MEDICAL OR VETERINARY SCIENCE; HYGIENE
KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
31Medicinal preparations containing organic active ingredients
33Heterocyclic compounds
395having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
 Appl.No PCT/US2025/035911 Applicant CASE WESTERN RESERVE UNIVERSITY Inventor MARKOWITZ, Sanford
A method of treating diseases or disorders characterized by structural deterioration of the blood-brain barrier or increased generation of reactive oxygen species within the nervous system of a subject in need thereof includes administering to the subject an amount of a 15-PGDH inhibitor and/or 15-PGDH substrate.
8.WO/2026/006593SYNTHETIC INTERNAL RIBOSOME ENTRY SITES
WO - 02.01.2026
Int.Class C12N 15/85
CCHEMISTRY; METALLURGY
12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
15Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
09Recombinant DNA-technology
63Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
79Vectors or expression systems specially adapted for eukaryotic hosts
85for animal cells
 Appl.No PCT/US2025/035485 Applicant ORNA THERAPEUTICS, INC. Inventor VUNGUTUR, Rahul
Circular RNA and precursor RNA polynucleotides comprising synthetic, non-naturally occurring, Internal Ribosome Entry Sites (IRES), along with related compositions and methods are described herein. In some embodiments, the synthetic IRESs comprise at least one addition, deletion, or substitution of a nucleotide, domain, or motif, as compared to a naturally occurring IRES. In some embodiments, the synthetic IRESs have improved function and/or expression and/or stability as compared to a naturally occurring IRES and/or are capable of increasing expression of operably linked expression sequences as compared to naturally occurring IRESs. Also presented herein are methods and compositions for the manufacture and preparation of the circularized RNAs comprising the synthetic IRESs, along with methods of administering said circular RNAs and related compositions to a subject in need thereof for treatment or prevention purposes.
9.WO/2026/006203COMPOSITIONS AND METHODS FOR MAKING CIRCULAR RNA
WO - 02.01.2026
Int.Class C12N 15/85
CCHEMISTRY; METALLURGY
12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
15Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
09Recombinant DNA-technology
63Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
79Vectors or expression systems specially adapted for eukaryotic hosts
85for animal cells
 Appl.No PCT/US2025/034866 Applicant ORBITAL THERAPEUTICS, INC. Inventor VENKATARAMANAN, Srivats
The present invention provides nucleic acids and methods for making circular RNAs (circRNAs), compositions comprising circular RNAs, and methods of use thereof. The present invention uses optimized self-splicing T4 bacteriophage td gene (T4td) intron sequences to produce circular RNAs. The optimized T4td intron sequences described herein mediate efficient circularization of a linear RNA sequence.
10.WO/2026/006687CIRCULAR RNA COMPOSITIONS AND USES THEREOF FOR DISEASES CAUSED BY VARICELLA-ZOSTER VIRUS
WO - 02.01.2026
Int.Class A61K 39/12
AHUMAN NECESSITIES
61MEDICAL OR VETERINARY SCIENCE; HYGIENE
KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
39Medicinal preparations containing antigens or antibodies
12Viral antigens
 Appl.No PCT/US2025/035631 Applicant ORBITAL THERAPEUTICS, INC. Inventor BESIN, Gilles
The present disclosure relates to circular RNA sequences encoding an antigen from varicella zoster virus (VZV). The circular RNA sequences described herein are used as vaccines and compositions for preventing or treating diseases resulting from VZV, including shingles. Methods of use, including methods of treating or preventing a disease caused by VZV and methods for formulating and preparing the VZV vaccine compositions, are also described.
# -